Today's proposal to increase those fees by $ 1 billion may not sound ominous in itself, but it implies an impending, equivalent cut to federal funding, says Steven Grossman, deputy executive director at the Alliance for a Stronger FDA in Washington, D.C.. That's an unrealistic
expectation, he adds, because drug companies have
already gone through negotiations and
reached an agreement with FDA on user fee increases.